Francesca Galbiati, Franziska Plessow, Lacey Plummer, Mark B Campbell, Shawn Nazarloo, C Sue Carter, Rona S Carroll, Han K Kim, Sidney A Pereira, Daria Paulis, John M Davis, Karen K Miller, Ursula B Kaiser, Stephanie B Seminara, Anna Aulinas, Elizabeth A Lawson
{"title":"人类静脉注射kisspeptin后催产素水平的性别依赖性增加。","authors":"Francesca Galbiati, Franziska Plessow, Lacey Plummer, Mark B Campbell, Shawn Nazarloo, C Sue Carter, Rona S Carroll, Han K Kim, Sidney A Pereira, Daria Paulis, John M Davis, Karen K Miller, Ursula B Kaiser, Stephanie B Seminara, Anna Aulinas, Elizabeth A Lawson","doi":"10.1093/ejendo/lvaf001","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A clinically significant oxytocin-deficient state (OXT-D) has been established in adults with arginine vasopressin deficiency, and there is a need to develop diagnostic testing. Kisspeptin (KP) is a candidate for such a test, as KP receptors are found on oxytocinergic neurons, and KP administration increases plasma OXT in animals. We hypothesized that intravenous KP administration would increase peripheral OXT levels post-injection in healthy adults.</p><p><strong>Methods: </strong>Kisspeptin-112-121 (KP analog, 0.24 nmol/kg bolus) was administered to 12 healthy adults (50% female). Serum OXT was measured before and 10, 20, 40, and 60 min after KP administration.</p><p><strong>Results: </strong>Males and females did not differ significantly in age, BMI, or baseline OXT levels. Ten minutes after KP, OXT increased by 18.8% from baseline (FDR-P = .004) with a greater increase in males than females (31.9% vs 5.7%, respectively, FDR-P = .004).</p><p><strong>Conclusions: </strong>Our data support KP as a candidate for a provocative test to identify OXT-D in males.</p><p><strong>Clinical trial registration: </strong>Our study was registered on ClinicalTrials.gov (NCT00914823).</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"K24-K29"},"PeriodicalIF":5.3000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886556/pdf/","citationCount":"0","resultStr":"{\"title\":\"Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans.\",\"authors\":\"Francesca Galbiati, Franziska Plessow, Lacey Plummer, Mark B Campbell, Shawn Nazarloo, C Sue Carter, Rona S Carroll, Han K Kim, Sidney A Pereira, Daria Paulis, John M Davis, Karen K Miller, Ursula B Kaiser, Stephanie B Seminara, Anna Aulinas, Elizabeth A Lawson\",\"doi\":\"10.1093/ejendo/lvaf001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>A clinically significant oxytocin-deficient state (OXT-D) has been established in adults with arginine vasopressin deficiency, and there is a need to develop diagnostic testing. Kisspeptin (KP) is a candidate for such a test, as KP receptors are found on oxytocinergic neurons, and KP administration increases plasma OXT in animals. We hypothesized that intravenous KP administration would increase peripheral OXT levels post-injection in healthy adults.</p><p><strong>Methods: </strong>Kisspeptin-112-121 (KP analog, 0.24 nmol/kg bolus) was administered to 12 healthy adults (50% female). Serum OXT was measured before and 10, 20, 40, and 60 min after KP administration.</p><p><strong>Results: </strong>Males and females did not differ significantly in age, BMI, or baseline OXT levels. Ten minutes after KP, OXT increased by 18.8% from baseline (FDR-P = .004) with a greater increase in males than females (31.9% vs 5.7%, respectively, FDR-P = .004).</p><p><strong>Conclusions: </strong>Our data support KP as a candidate for a provocative test to identify OXT-D in males.</p><p><strong>Clinical trial registration: </strong>Our study was registered on ClinicalTrials.gov (NCT00914823).</p>\",\"PeriodicalId\":11884,\"journal\":{\"name\":\"European Journal of Endocrinology\",\"volume\":\" \",\"pages\":\"K24-K29\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886556/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Endocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ejendo/lvaf001\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ejendo/lvaf001","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans.
Background: A clinically significant oxytocin-deficient state (OXT-D) has been established in adults with arginine vasopressin deficiency, and there is a need to develop diagnostic testing. Kisspeptin (KP) is a candidate for such a test, as KP receptors are found on oxytocinergic neurons, and KP administration increases plasma OXT in animals. We hypothesized that intravenous KP administration would increase peripheral OXT levels post-injection in healthy adults.
Methods: Kisspeptin-112-121 (KP analog, 0.24 nmol/kg bolus) was administered to 12 healthy adults (50% female). Serum OXT was measured before and 10, 20, 40, and 60 min after KP administration.
Results: Males and females did not differ significantly in age, BMI, or baseline OXT levels. Ten minutes after KP, OXT increased by 18.8% from baseline (FDR-P = .004) with a greater increase in males than females (31.9% vs 5.7%, respectively, FDR-P = .004).
Conclusions: Our data support KP as a candidate for a provocative test to identify OXT-D in males.
Clinical trial registration: Our study was registered on ClinicalTrials.gov (NCT00914823).
期刊介绍：
European Journal of Endocrinology is the official journal of the European Society of Endocrinology. Its predecessor journal is Acta Endocrinologica.
The journal publishes high-quality original clinical and translational research papers and reviews in paediatric and adult endocrinology, as well as clinical practice guidelines, position statements and debates. Case reports will only be considered if they represent exceptional insights or advances in clinical endocrinology.
Topics covered include, but are not limited to, Adrenal and Steroid, Bone and Mineral Metabolism, Hormones and Cancer, Pituitary and Hypothalamus, Thyroid and Reproduction. In the field of Diabetes, Obesity and Metabolism we welcome manuscripts addressing endocrine mechanisms of disease and its complications, management of obesity/diabetes in the context of other endocrine conditions, or aspects of complex disease management. Reports may encompass natural history studies, mechanistic studies, or clinical trials.
Equal consideration is given to all manuscripts in English from any country.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
